REPROCELL Europe Ltd
http://www.reprocell.com/
REPROCELL Europe Ltd is a Contract Research Organisation specialising in the use of fresh human tissues to better predict drug efficacy and safety during non-clinical drug development. We source a range of fresh healthy and diseased tissues from multiple providers, across the UK, Europe and the USA, for specific academic and pharmaceutical industry sponsored projects conducted within REPROCELL facilities. Services utilising fresh tissue include pharmacological assays, 3-D culture and induced pluripotent stem cell production using our exclusive RNA re-programming technology. Through our REPROCELL partner group we also have access to a global biorepository of human serum, DNA, RNA and FFPE samples.
Services
- Cell culture
- Human functional tissue assays
- IPSC reprogramming services
- Nucleic acid extraction
Bespoke collection capabilities:
- Asthma (disorder)
- Chronic obstructive lung disease (disorder)
- Diabetes mellitus type 1 (disorder)
- Diabetes mellitus type 2 (disorder)
- Fit and well (finding)
- Hypertensive disorder, systemic arterial (disorder)
- Inflammatory bowel disease (disorder)
- Ischemic heart disease (disorder)
Networks
- Scientist.com Our collaboration with UK CRC TCC is to simplify and improve the access to human biosamples. We understand that it is vital that a Biobank has fully visibility to the research organisation, the researcher to be conducted and control who samples are provided to. As such we have built our platform specifically to address these requirements. Through the platform a biobank can get immediate access to: • A contract specifically designed for the provision of biospecimens that has been accepted by all our clients and results in a direct contractual relationship between the researcher and biobank. • Access to our COMPLi functionality to simplify and speed up the process to work with researchers • Access to a dedicated team to support your biobank in responding to request. • A cost neutral solution to support sustainability within the biobank community. Our work supporting the provision of human biospecimens began in 2014 and since then we have launched our COMPLi™ functionality to support and facilitate over 6500 projects, involving the sourcing of human samples, by removing the administrative burden whilst supporting sustainability within Biobanks. Our aim is to facilitate direct, controlled interactions between the sources of samples and researchers that results in a direct contractual relationship and supports the required level of transparency needed by both parties. If you are interested in joining the platform please do not hesitate to get in touch. Background Founded in 2007, Scientist.com is the world's leading and fastest-growing marketplace for outsourced scientific services and human biological samples. Scientist.com significantly simplifies research by saving time and money and providing easy access to innovative tools and technologies - while maintaining full compliance with an organization’s procurement policies be that researcher or provider. We operate private marketplaces for most of the world’s major pharmaceutical companies and the US National Institutes of Health (NIH); other clients include large and small biotechnology companies, academic researchers and citizen scientists.
Contact Information
- Email:
- info-emea@reprocell.com
- Address:
-
Thomson Pavilion
Todd Campus
West of Scotland Science Park
Acre Road
Glasgow
Glasgow (City of)
G20 0XA
Scotland
Last Updated: 06/05/2018
Annual Statistics
Year | Access Requests Received | Access Requests Approved | ||||
---|---|---|---|---|---|---|
Internal | External | Commercial | Internal | External | Commercial | |
2015 | N/A | N/A | N/A | N/A | N/A | N/A |
2016 | N/A | N/A | N/A | N/A | N/A | N/A |
2017 | N/A | N/A | N/A | N/A | N/A | N/A |
2018 | N/A | N/A | N/A | N/A | N/A | N/A |
2019 | N/A | N/A | N/A | N/A | N/A | N/A |
2020 | N/A | N/A | N/A | N/A | N/A | N/A |
2021 | N/A | N/A | N/A | N/A | N/A | N/A |
2022 | N/A | N/A | N/A | N/A | N/A | N/A |
2023 | N/A | N/A | N/A | N/A | N/A | N/A |
2024 | N/A | N/A | N/A | N/A | N/A | N/A |